Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

• Conditions: Chronic Lymphocytic Leukemia
• Interventions: Drug: Chlorambucil; Drug: R-etodolac + chlorambucil

• Registration Number: NCT00151736
• Lead Sponsor: Cephalon

Brief Summary

This is a Phase 2, multi-center, open label, randomized clinical study to evaluate the safety and efficiency of SDX-101 in combination with chlorambucil (CLB) and chlorambucil alone in Chronic Lymphocytic Leukaemia (CLL) patients. The study treatment period will be approximately 24-26 weeks with a follow-up period of approximately 8 weeks. Following the end of treatment, patients with a confirmed complete response, partial response or stable disease will be followed for up to 2 years to assess time to disease progression. Approximately 80 patients with documented diagnosis of B-cell CLL by standard clinical and immunophenotyping criteria will be enrolled into the SDX-101-03 study. This study is being conducted in the following European countries: France, Germany, Poland, Sweden and the United Kingdom.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09
• Study First Submitted: 2005-09-07
• Study First Submitted QC: 2005-09-07
• Study First Posted: 2005-09-09
• Primary Completion: 2006-02
• Study Completion: 2008-02
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-08
• Last Update Posted: 2012-06-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

1. Diagnosis of B-cell CLL by standard clinical and immunophenotypic criteria as specified by the NCI working group revised guidelines for diagnosis and treatment of CLL(32).

2. Binet stages A-C with evidence of active disease requiring treatment by the presence of one or more of the following at the time of study entry:

   • Disease related B symptoms (Fever > 38C [100.5F] for ≥ 2 weeks without evidence of infection, night sweats without evidence of infection, weight loss > 10% within previous 6 mo.).
   • Evidence of progressive marrow failure as manifested by:
   • A decrease in hemoglobin to < 10g/dL, or
   • A decrease in platelet count to < 100 x 10(9)/L within the previous 6 months, or
   • A decrease in absolute neutrophil count (ANC) to < 1.0 x 10(9)/L within 6 months
   • Progressive lymphocytosis with an increase of > 50% over a 2 month period, or an anticipated doubling time of < 6 months.
   • Massive nodes or clusters(i.e., > 10 cm in longest diameter) or progressive lymphadenopathy.
   • Progressive splenomegaly to > 2cm below the left costal margin or other organomegaly with progressive increase over 2 consecutive clinical visits ≥ 2 weeks apart.

3. No prior chemotherapy for CLL.

4. Age ≥ 18 at signing of informed consent.

5. World Health Organization (WHO) performance status ≤ 0-2 (Appendix B).

6. Platelet count > 50,000/μL, hemoglobin > 8.0 g/dl and absolute neutrophil count > 1000/μL.

7. Renal function ≤ 1.5 x upper limit normal (blood urea nitrogen [BUN], serum creatinine)

8. Liver function ≤ 1.5 times upper limit of normal (total bilirubin, SGOT (AST) and SGPT (ALT) values).

9. Female patients of childbearing potential must have a negative pregnancy test (serum or urine Beta-human chorionic gonadotropin, Beta-HCG); men and women of reproductive potential must employ effective contraceptive methods while on study therapy, and for 2 months following completion of treatment.

10. Signed EC/IRB-approved informed consent by patient prior to all study related procedures.

Read More

Exclusion Criteria

1. Active autoimmune manifestation of CLL such as ongoing hemolytic anemia or ITP
2. History of a second malignancy with the exception of cervical cancer,or resected basal cell carcinoma or other malignancies with no evidence of recurrence 5 or more years since diagnosis.
3. Chronic viral infection: positive hepatitis B or hepatitis C serology, known positive for human immunodeficiency virus (HIV) or human T-leukemia/lymphoma virus (HTLV).
4. Transformation to an aggressive B-cell malignancy such as Richter's transformation, prolymphocytic leukemia (PLL) or large B-cell lymphoma.
5. Clinical evidence of CNS involvement with CLL.
6. Serious infection, medical condition, or psychiatric condition that, in the opinion of the investigator, might interfere with the achievement of the study objectives.
7. Treatment with any investigational agent within 4 weeks of study entry.
8. The use of steroids, nonsteroidal anti-inflammatory drugs, regardless of indication (excluding prophylactic use of aspirin for prevention of acute myocardial infarction or stroke)
9. Pregnancy or currently breast feeding.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Chlorambucil	Chlorambucil	Regime A
R-etodolac with chlorambucil	R-etodolac + chlorambucil	Regime B

Primary Outcome Measures

Name	Time	Method
Bone Marrow Biopsy or Aspiration	Baseline + 6 months	Overall response rate assessment according to National Cancer Institute-Working Group (NCI-WG) criteria using cytogenetic and biomarker evaluations.

Secondary Outcome Measures

Name	Time	Method
Cytogenetic and biomarker evaluations + adverse events	6 months	Cytogenetic and biomarker evaluations performed on day 14 (for regimen B) and day 1 (for regimen A) to assess Safety and Tolerability. Study visits to assess safety occur every 2 weeks for 3 months, then every month thereafter. Safety assessments include: medical history, physical examinations, vital sign measurements, adverse event assessment, routine hematology and serum chemistry tests, urinalysis, and ECGs.

Trial Locations

Locations (22)

Service maladies du sang CHRU- rue Michel Polonovski; 🇫🇷 Lille, France

Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Klinika Hematologii Instytutu Medycyny Wewnetrznej Uniwersytetu Medycznego w Lodzi; 🇵🇱 Lodz, Poland

Medizinische Poliklinik der Universität Hämatologie/Onkologie; 🇩🇪 Würzburg, Germany

Samodzielny Publiczny Szpital Kliniczny Nr 1 Akademickie Centrum Kliniczne Akdemii Medycznej w Gdansku Klinika Hematologii; 🇵🇱 Gdansk, Poland

Hematologkliniken Karolinska Universitetssjukhuset, Huddinge; 🇸🇪 Stockholm, Sweden

Uniwersytet Jagiellonski Collegium Medicum Katedra i Klinika Hematologii; 🇵🇱 Krakow, Poland

Prywatna Praktyka Lekarska z Osrodkiem Badan Klinicznych Prof. L. Szczepanskiego; 🇵🇱 Lublin, Poland

Hematologisektionen Medicincentrum Akademiska sjukhuset; 🇸🇪 Uppsala, Sweden

Charité - Benjamin Franklin Medizinische Klinik III Hämatologie, Onkologie und Transfusionsmedizin; 🇩🇪 Berlin, Germany

Chef du Service d'Hematologie Clinique CHU Clemenceau; 🇫🇷 Caen, France

Internistische Schwerpunktpraxis; 🇩🇪 Erlangen, Germany

Samodzielny Publiczny Szpital Kliniczny AM Klinika Hematologii; 🇵🇱 Bialystok, Poland

Samodzielny Publiczny Szpital Kliniczny Nr 1 Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku; 🇵🇱 Wroclaw, Poland

Centrum för Hematologi Karolinska Universitetssjukhuset, Solna; 🇸🇪 Stockholm, Sweden

Samodzielny Publiczny Centralny Szpital Kliniczny Katedra i Klinika Hematologii Onkologii i Chorob Wewnetrznych AM; 🇵🇱 Warszawa, Poland

Cardiff and Vale NHS Trust University Hospital of Wales; 🇬🇧 Cardiff, United Kingdom

Hematologkliniken Norrlands Universitetssjukhus; 🇸🇪 Umeå, Sweden

Royal Bournemouth Hospital Dept. of Haematology; 🇬🇧 Bournemouth, United Kingdom

Stobhill Hospital Department of Haematology; 🇬🇧 Glasgow, United Kingdom

Leeds General Infirmary Department of Haematology; 🇬🇧 Leeds, United Kingdom

Leicester Royal Infirmary Department of Oncology & Haematology; 🇬🇧 Leicester, United Kingdom

Nottingham City Hospital NHS Trust; 🇬🇧 Nottingham, United Kingdom